Lataa...
Pairing JAK with MEK for improved therapeutic efficiency in myeloproliferative disorders
The identification of JAK2 mutations as disease-initiating in myeloproliferative neoplasms (MPNs) has led to new and effective therapies for these diseases. In a study published in this issue of the JCI, Stivala et al. explored the key observation that JAK inhibition successfully suppresses MAPK act...
Tallennettuna:
| Julkaisussa: | J Clin Invest |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Clinical Investigation
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436870/ https://ncbi.nlm.nih.gov/pubmed/30829649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI127582 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|